EMA Withdrawn: Eksunbi (ustekinumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

The EMA has withdrawn Eksunbi (ustekinumab) from the European market as of 23 May 2025, affecting indications for Crohn's disease, ulcerative colitis, psoriasis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• Eksunbi (ustekinumab)

Snippet

Status: Withdrawn. Therapeutic area: Crohn Disease;Colitis, Ulcerative;Psoriasis;Arthritis, Psoriatic. MAH: Samsung Bioepis NL B.V.. Decision date: 23/05/2025